Irvine, California (ots/PRNewswire) - - Special Stockholders Meeting to Approve Merger With Integra on October 11, 2007 IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced the filing of a definitive proxy statement with the U.S. Securities and Exchange Commission ("SEC") in connection with the IsoTis-Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") combination. ...
Vienna, Austria (ots/PRNewswire) - - New analyses presented in Europe for the first time underscores REACH implications for individuals with leg artery blockages - Findings suggest the need for earlier, more aggressive therapeutic intervention New analyses from the REACH Registry presented at the ...
Seoul, Korea (ots/PRNewswire) - Patients worldwide with advanced lung cancer can expect longer survival according to new data from the TRUST study presented at the 12th World Conference on Lung Cancer (WCLC) in Seoul, Korea. These new worldwide observations show that patients suffering from non-small cell lung cancer (NSCLC) and treated with Tarceva (erlotinib) in routine clinical practice are experiencing ...
Ingelheim, Germany (ots/PRNewswire) - Constipation is a condition that we are all familiar with, however, according to new international research from Dulcolax(R), constipation actually affects much more than just bowel movements and can have a severely detrimental impact on people's quality of life, in some cases comparable to that experienced by people suffering from more serious ailments. The Dulcolax(R) survey ...
Paris (ots/PRNewswire) - Sanofi-aventis announced today that one year findings from the landmark ExTRACT-TIMI 25 and STEEPLE studies confirm clear net clinical benefit for patients with acute ST-segment elevation myocardial infarction (STEMI) for Lovenox(R) vs Unfractionnated Heparin (UFH). The ExTRACT-TIMI ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 6-month report 31.08.2007 Pfaeffikon SZ, 31 August 2007 --- In the first half year of 2007 shaPE achieved continued solid results as illustrated by the 17.5% increase in the Net Asset Value ...
Callisto Pharmaceuticals. Inc.
New York (ots/PRNewswire) - Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders and diseases, today announced that the staff of the American Stock Exchange ("AMEX") has reviewed the Company's plan of compliance ...
London (ots/PRNewswire) - - For International Medical Journalists Only AstraZeneca today announced the Netherlands regulatory authority MEB (Medicines Evaluation Board) has approved SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets, a once-daily medicine for the treatment of schizophrenia in ...
Minneapolis (ots/PRNewswire) - AGA Medical Corporation ("AGA") announced today that it has received U.S. Food and Drug Administration (FDA) and European CE Mark approvals for the AMPLATZER Vascular Plug II ("vascular plug II"). The AMPLATZER Vascular Plug II expands the AGA family of occlusion devices designed to embolize, or close blood vessel and blood ...
Basel, Switzerland (ots/PRNewswire) - - First Medicine Shown to Extend Survival Beyond One Year in Previously Untreated Lung Cancer Patients Avastin (bevacizumab), Roche's innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), in combination with platinum-based ...
Basel, Switzerland (ots/PRNewswire) - The World Health Organization (WHO) has reinforced that Tamiflu (oseltamivir) is the primary recommended antiviral of choice in managing patients infected with H5N1 in updated guidance published on the WHO website today. Experts believe that a human influenza pandemic is imminent and could be triggered by the highly pathogenic ...
Calgary, Canada (ots/PRNewswire) - - Canadian Biotechnology Company Confirms Commercial Expression Levels of Apo AI Milano Variant and Clarifies Status of Native Apo AI SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today updated a release issued on July 12, 2007 announcing that the Company had achieved ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that it received a letter dated August 15, 2007 from the US Food and Drug Administration ("FDA"), clearing the Accell Family of Products for marketing in the US as Class II medical devices. The Accell Family of Products includes Accell 100, Accell Connexus and Accell Total Bone Matrix, as well as ...
Maidenhead, England (ots/PRNewswire) - - Enhancements Provide Haemophilia B Patients with a Simpler and More Convenient Preparation Process for Recombinant Factor IX - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has received approval from the European Medicines Agency (EMEA) for new enhancements for BeneFix(R) nonacog ...
Callisto Pharmaceuticals. Inc.
New York (ots/PRNewswire) - Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and inflammatory diseases, announced today the addition of two sites to its Phase II clinical trial of Atiprimod to treat low to intermediate grade neuroendocrine ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc (NASDAQ: ISOT), an orthobiologics company, today reported its results for the second quarter and six months ended June 30, 2007. Product revenues were $10.4 million for the second quarter of 2007, representing a 4% decrease over product revenues of $10.8 million for the second quarter of 2006. For the first six ...
Integra LifeSciences Holdings Corporation and IsoTis, Inc.
Plainsboro, New Jersey and Irvine, California (ots/PRNewswire) - - Creating a Global Leader in Orthobiologics Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") and IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis") announced today a definitive agreement whereby Integra would acquire IsoTis in an all cash transaction. This strategic combination, unanimously approved by the Board of Directors of IsoTis, ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDQ: ISOT), a leading orthobiologics company, will release its 2007 second quarter results before opening of trading on Tuesday, August 7, 2007. To discuss these results, the Company will conduct a conference call at 4:00 p.m. (Eastern Time) / 1:00 p.m. (Pacific Time)/ 10:00 p.m. (Central European Time). Dial in details will be provided in the Q2 2007 release on ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika today announced that the Company has received permission from the Food and Drug Administration of the United States (FDA) for the long term use of ISA247 in patients currently participating in the Company's Phase 2b kidney transplant (PROMISE) trial. The Company previously announced in June that it had also ...
King Of Prussia, Pennsylvania (ots/PRNewswire) - MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, announced today the expansion of its Development & Regulatory Services (DRS) business in Europe. MDS Pharma Services will now offer full-service DRS consulting services to support development of new drugs and ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) announced today that the European Agency for the Evaluation of Medicinal Products (EMEA) committee for Orphan Medicinal Products has adopted a positive opinion on orphan medicinal product designation for ISA247 for the treatment of chronic, ...
Oss, The Netherlands (ots/PRNewswire) - Organon, the human healthcare business unit of Akzo Nobel (Euronext Amsterdam: AKZ), today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved rocuronium bromide, its neuromuscular blocking agent (NMBA) for use during general anesthesia, under the brand name Eslax(R). This drug has a fast onset of action and is one of the most widely used muscle ...
Minneapolis (ots/PRNewswire) - AGA Medical Corporation ("AGA") today announced that it has won its patent infringement lawsuit against Occlutech GmbH, headquartered in Jena, Germany, and DRABO Medizintechnik, located in Cologne, Germany. AGA is the owner of a European patent (EP 0 808 138) registered in Germany (DE 695 34 505) for intravascular occlusion devices ...
Basel, Switzerland (ots/PRNewswire) - - First Anti-Anaemia Product Offering Simple Once-Monthly Maintenance Treatment Roche announced today that the European Commission has approved its innovative drug MIRCERA to treat anaemia associated with chronic kidney disease (CKD). The approval of MIRCERA results in a single marketing authorisation with unified ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company ("IsoTis"), today announced that it has concluded the squeeze-out merger of ISOTIS SA following an Extraordinary General Meeting of shareholders on July 23, 2007. As a result, ISOTIS SA has merged with and into IsoTis International SA, a wholly-owned subsidiary of IsoTis, and no longer exists as a separate legal entity. After ...
Boehringer Ingelheim and Pfizer
Ingelheim, Germany (ots/PRNewswire) - - Patients to Benefit From Easy-to-Use Inhaler With Enhanced Drug Delivery Boehringer Ingelheim and Pfizer today announced successful completion of the approval process for authorisation to market SPIRIVA(R) Respimat(R) in the European Union for people with chronic obstructive pulmonary disease (COPD). This positive ...
Sydney, Australia (ots/PRNewswire) - New data from two new studies of Viramune(R) (nevirapine) were presented at the 4th International AIDS Society (IAS) in Sydney, Australia. Results from an extended three-year follow-up analysis of the 2NN study demonstrated that HIV-positive patients taking ...
Ingelheim, Germany (ots/PRNewswire) - - Trial to compare newest protease inhibitors in treatment-experienced patients with resistance to more than one PI Boehringer Ingelheim GmbH announced today that enrollment of the POTENT study will begin in August 2007. POTENT will compare the efficacy and safety ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) announced today that the Company has completed recruitment of its pivotal Phase 3 European/Canadian psoriasis trial (ESSENCE). As of July 20, 2007, the Company closed recruitment at 638 patients. The patient population is made up of 228 Canadian patients, 294 patients from Germany and 116 patients from ...
Sydney, Australia (ots/PRNewswire) - Recent launches of new protease inhibitors and the anticipated availability of new antiretroviral drug classes have increased the therapeutic options available to treatment-experienced HIV-positive patients, and made achieving an undetectable viral load a realistic goal ...